Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTVOE6D)

DTT Name Mitogen-activated protein kinase (MAPK)
Synonyms MAPK; Extracellular signal-regulated kinase; ERK
Gene Name MAPK
DTT Type
Clinical trial target
 [1]
BioChemical Class
Kinase
UniProt ID
NOUNIPROTAC
TTD ID
T25537

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
GBL-310 DM2IFJQ Keratosis ED56 Phase 2 [1]
LTT462 DM94E6W Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PF-07799544 DMAO10K Aggressive cancer 2A00-2F9Z Phase 1 [3]
------------------------------------------------------------------------------------
18 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bidentate ligands of Markush derivative 1 DMB08D3 N. A. N. A. Patented [4]
Bidentate ligands of Markush derivative 2 DM2QNMC N. A. N. A. Patented [4]
PMID25991433-Compound-B1 DMJTO69 N. A. N. A. Patented [5]
PMID25991433-Compound-B2 DMTYQOF N. A. N. A. Patented [5]
PMID25991433-Compound-B3 DMWSGV2 N. A. N. A. Patented [5]
PMID25991433-Compound-C2 DMOAU09 N. A. N. A. Patented [5]
PMID25991433-Compound-C3 DMSKWBE N. A. N. A. Patented [5]
PMID25991433-Compound-F1 DMFS2YL N. A. N. A. Patented [5]
PMID25991433-Compound-J1 DMQGUMN N. A. N. A. Patented [5]
PMID25991433-Compound-J6 DMOWULJ N. A. N. A. Patented [5]
PMID25991433-Compound-L DM5U8WT N. A. N. A. Patented [5]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [5]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [5]
PMID25991433-Compound-N2 DMXY4BE N. A. N. A. Patented [5]
PMID25991433-Compound-P2 DMEGS7U N. A. N. A. Patented [5]
PMID25991433-Compound-P3 DMAFZLP N. A. N. A. Patented [5]
PMID25991433-Compound-Q1 DMEMSB2 N. A. N. A. Patented [5]
PMID25991433-Compound-Q2 DMAIKJV N. A. N. A. Patented [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Patented Agent(s)
1 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
U0126 DM31OGF Discovery agent N.A. Investigative [6]
------------------------------------------------------------------------------------

References

1 WO patent application no. 2010,0456,51, Methods for analyzing drug response.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
4 Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
5 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
6 Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11569-74.